{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:05:43Z","timestamp":1768003543153,"version":"3.49.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,1,20]],"date-time":"2019-01-20T00:00:00Z","timestamp":1547942400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Greensboro CRS","award":["5UM1A069423-11"],"award-info":[{"award-number":["5UM1A069423-11"]}]},{"name":"Institute of Allergy and Infectious Diseases"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068634"],"award-info":[{"award-number":["UM1 AI068634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068636"],"award-info":[{"award-number":["UM1 AI068636"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI106701"],"award-info":[{"award-number":["UM1 AI106701"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1093\/jac\/dky564","type":"journal-article","created":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T23:26:01Z","timestamp":1546039561000},"page":"1376-1380","source":"Crossref","is-referenced-by-count":18,"title":["Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA &lt;500\u2009000 copies\/mL: week 48 outcomes from ACTG 5353"],"prefix":"10.1093","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1703-0500","authenticated-orcid":false,"given":"Amesika N","family":"Nyaku","sequence":"first","affiliation":[{"name":"Rutgers University, Newark, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Harvard T. H. Chan School of Public Health, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy M","family":"Gulick","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxine","family":"Olefsky","sequence":"additional","affiliation":[{"name":"Harvard T. H. Chan School of Public Health, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baiba","family":"Berzins","sequence":"additional","affiliation":[{"name":"Northwestern University, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole L","family":"Wallis","sequence":"additional","affiliation":[{"name":"BARC-SA and Lancet Laboratories, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Godfrey","sequence":"additional","affiliation":[{"name":"Division of AIDS, National Institutes of Allergy and Infectious Diseases, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul E","family":"Sax","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward P","family":"Acosta","sequence":"additional","affiliation":[{"name":"University of Alabama, Birmingham, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W","family":"Haas","sequence":"additional","affiliation":[{"name":"Vanderbilt University, Nashville, TN, USA"},{"name":"Meharry Medical College, Nashville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly Y","family":"Smith","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverly E","family":"Sha","sequence":"additional","affiliation":[{"name":"Rush University Medical Center, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelius N","family":"Van Dam","sequence":"additional","affiliation":[{"name":"Regional Center for Infectious Diseases, Cone Health, Greensboro, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babafemi O","family":"Taiwo","sequence":"additional","affiliation":[{"name":"Northwestern University, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"ACTG A5353 Study Team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnstone","family":"Kumwenda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadette","family":"Jarocki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Tegha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanisha","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"key":"2019042309333236600_dky564-B1","doi-asserted-by":"crossref","first-page":"21678.","DOI":"10.7448\/IAS.20.01.21678","article-title":"Dolutegravir\u2013lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study","volume":"20","author":"Cahn","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"2019042309333236600_dky564-B2","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/cid\/cix1083","article-title":"ACTG A5353: a pilot study of dolutegravir plus lamivudine for initial treatment of human immunodeficiency virus-1 (HIV-1)-infected participants with HIV-1 RNA <500000 copies\/mL","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019042309333236600_dky564-B3","volume-title":"Abstracts of Ninth International AIDS Society Conference on HIV Science, Paris, France","author":"Figueroa","year":"2017"},{"key":"2019042309333236600_dky564-B4","first-page":"642","article-title":"Special contribution 2014 update of the drug resistance mutations in HIV-1","volume":"22","author":"Wensing","year":"2014","journal-title":"Top Antivir Med"},{"key":"2019042309333236600_dky564-B5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/09540120050042891","article-title":"Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG)","volume":"12","author":"Chesney","year":"2000","journal-title":"AIDS Care"},{"key":"2019042309333236600_dky564-B6","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"2019042309333236600_dky564-B7","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2019042309333236600_dky564-B8","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir\u2013lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"2019042309333236600_dky564-B9","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"379","author":"DeJesus","year":"2012","journal-title":"Lancet"},{"key":"2019042309333236600_dky564-B10","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"2019042309333236600_dky564-B11","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"2019042309333236600_dky564-B12","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"2019042309333236600_dky564-B13"},{"key":"2019042309333236600_dky564-B14","volume-title":"Symposium Session: Safety of Dolutegravir in Pregnancy. Twenty-second International AIDS Conference, Amsterdam, The Netherlands","author":"Zash","year":"2018"},{"key":"2019042309333236600_dky564-B15","year":"2018"},{"key":"2019042309333236600_dky564-B16","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","author":"Cahn","year":"2018","journal-title":"Lancet"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/5\/1376\/28501295\/dky564.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T09:36:46Z","timestamp":1556012206000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/5\/1376\/5296308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":16,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,1,18]]},"published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky564","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2019,1,18]]}}}